Contemporary management of coronary artery disease and acute coronary syndrome in patients with chronic kidney disease and end-stage renal disease

Acta Cardiologica Sinica

Volumn 29, Issue 2, 2013, Pages 132-141

  Huang, Chin Chou ^a,b   Chen, Jaw Wen ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Acute coronary syndrome; Chronic kidney disease; Coronary artery disease; Diagnosis; End stage renal disease; Management

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CLOPIDOGREL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; STATIN (PROTEIN);

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; BLEEDING; BLEEDING TIME; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY RECANALIZATION; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG EFFICACY; DYSPNEA; GLOMERULUS FILTRATION RATE; HEART BUNDLE BRANCH BLOCK; HEART CATHETERIZATION; HEART DEATH; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REVASCULARIZATION; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LONG TERM SURVIVAL; METABOLIC SYNDROME X; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SUDDEN CARDIAC DEATH; TAIWAN; THORAX PAIN; THROMBOCYTE AGGREGATION;

EID: 84878334842     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. El Nahas AM, Bello AK. Chronic kidney disease: the global chal-lenge. Lancet 2005;365: 331-40.
2. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement fromKidney Disease Improving Global outcomes. Kidney Int 2007;72: 247-59.
3. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298: 2038-47.
4. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002; 13:S37-40.
5. Smith DH, Gullion CM, Nichols G, et al. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol 2004;15: 1300-6.
6. USRDS. International comparisons. In: United Stated Renal Data System Annual Data Report. Bethesda, MD: The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease 2009;344-55.
7. Hsu CC, Hwang SJ,Wen CP, et al. High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. Am J Kidney Dis 2006;48: 727-38.
8. Kuo HW, Tsai SS, Tiao MM, et al. Epidemiological features of CKD in Taiwan. Am J Kidney Dis 2007;49: 46-55.
9. Wen CP, Cheng TY, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008;371: 2173-82.
10. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351: 1296-305.
11. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116: 85-97.
12. Wattanakit K, Kushman M, Stehman-Breen C, et al. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 2008;19: 135-40.
13. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J AmSoc Nephrol 2004;15: 1307-15.
14. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000;356: 147-52.
15. Iseki K, Fukiyama K. Long-term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis. The Okinawa Dialysis Study Group. Am J Kidney Dis 2000;36: 820-5.
16. de Jager DJ, Grootendorst DC, Jager KJ, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009;302: 1782-9.
17. Chien KL, Hsu HC, Lee YT, et al. Renal function and metabolic syndrome components on cardiovascular and all-cause mortality. Atherosclerosis 2008,197: 860-7.
18. Hwang SJ, LinMY, Chen HC, et al. Increased risk of mortality in the elderly population with late-stage chronic kidney disease: a cohort study in Taiwan. Nephrol Dial Transplant 2008;23: 3192-8.
19. Chou MT, Wang JJ, Sun YM, et al. Epidemiology and mortality among dialysis patients with acute coronary syndrome: Taiwan National Cohort Study. Int J Cardiol 2012 Jul 12. [Epub ahead of print]
20. Hsieh TH,Wang JD, Tsai LM. Improving in-hospital mortality in elderly patients after acute coronary syndrome a nationwide analysis of 97,220 patients in Taiwan during 2004-2008. Int J Cardiol 2012;155: 149-54.
21. Foley RN, Herzog CA, Collins AJ. Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 study. Kidney Int 2003;63: 1462-7.
22. Sosnov J, Lessard D, Goldberg RJ, et al. Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective. Am J Kidney Dis 2006;47: 378-84.
23. Herzog CA, Littrell K, Arko C, et al. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 2007;116: 1465-72.
24. Shroff GR, Frederick PD, Herzog CA. Renal failure and acutemyocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry ofMyocardial Infarction.AmHeart J 2012;163: 399-406.
25. Fox CS, Muntner P, Chen AY, et al. Acute Coronary Treatment and Intervention Outcomes Network Registry. Use of evidencebased therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 2010;121: 357-65.
26. Szummer K, Lundman P, Jacobson SH, et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Circulation 2009;120: 851-8.
27. Gurm HS, Gore JM, Anderson FA Jr, et al. Global Registry of Acute Coronary Events (GRACE) Investigators. Comparison of acute coronary syndrome in patients receiving versus not receiving chronic dialysis (from the Global Registry of Acute Coronary Events [GRACE] Registry). Am J Cardiol 2012;109: 19-25.
28. Thygesen K, Alpert JS, Jaffe AS, et al. Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Circulation 2012;126: 2020-35.
29. NACB Writing Group, Wu AH, Jaffe AS, Apple FS, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem 2007;53: 2086-96.
30. Jacobs LH, van de Kerkhof J, Mingels AM, et al. Haemodialysis patients longitudinally assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and cardiac troponin I assays. Ann Clin Biochem 2009;46: 283-90.
31. Anavekar NS, McMurray JJ, Velazquez E, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl JMed 2004;351: 1285-95.
32. Keough-Ryan TM, Kiberd BA, Dipchand CS, et al. Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia. Am J Kidney Dis 2005;46: 845-55.
33. Melloni C, Peterson ED, Chen AY, et al. Cockcroft-gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2008;51: 991-6.
34. Han JH, Chandra A, Mulgund J, et al. Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. Am JMed 2006;119: 248-54.
35. Santopinto JJ, Fox KA, Goldberg RJ, et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE). Heart 2003;89: 1003-8.
36. Herzog CA,Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002;106: 2207-11.
37. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002;137: 563-70.
38. Pun PH, Smarz TR, Honeycutt EF, et al. Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. Kidney Int 2009;76: 652-8.
39. Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002;39: 1113-9.
40. Chien KL, Lin HJ, Hsu HC, et al. Lipid-related residual risk and renal function for occurrence and prognosis among patients with first-event acute coronary syndrome and normal LDL cholesterol. Lipids Health Dis 2011;10:215.
41. Chen HH, Wu CJ, Chen YC, et al. Metabolic syndrome is associated with severe coronary artery disease and poor cardiac outcome in end-stage renal disease patients with acute coronary syndrome. Coron Artery Dis 2006;17: 593-6.
42. McCullough PA. Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? J Am Coll Cardiol 2003;41: 725-8.
43. Amann K, Wanner C, Ritz E. Cross-talk between the kidney and the cardiovascular system. J Am Soc Nephrol 2006;17: 2112-9.
44. Ford ML, Tomlinson LA, Chapman TP, et al. Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4. Hypertension 2010;55: 1110-5.
45. Tonelli M,Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17: 2034-47.
46. Rodriguez-Iturbe B, Correa-Rotter R. Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease. Expert Opin Pharmacother 2010;11: 2687-98.
47. Zoccali C, Benedetto FA, Tripepi G, et al. Left ventricular systolic function monitoring in asymptomatic dialysis patients: a prospective cohort study. J Am Soc Nephrol 2006;17:14605.
48. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-STsegment elevation acute coronary syndromes. JAMA 2005;294: 3108-16.
49. Fox KA, Bassand JP, Mehta SR, et al. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med 2007;147: 304-10.
50. Szummer K, Lundman P, Jacobson SH, et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Circulation 2009;120: 851-8.
51. Bonello L, De Labriolle A, Roy P, et al. Impact of optimal medical therapy and revascularization on outcome of patients with chronic kidney disease and on dialysis who presented with acute coronary syndrome. Am J Cardiol 2008;102: 535-40.
52. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acutemyocardial infarction. J Am Coll Cardiol 2003;42: 201-8.
53. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease fromclinical trials in coronary artery disease. Kidney Int 2006;70: 2021-30.
54. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/ Non ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2007;50: 652-726.
55. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324: 71-86.
56. Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol 2010;56: 956-65.
57. Washam JB, Adams G. Risks and benefits of antiplatelet therapy in uremic patients. Adv Chronic Kidney Dis 2008;15: 370-7.
58. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000;321: 1183-7.
59. Remuzzi G. Bleeding in renal failure. Lancet 1988;1: 1205-8.
60. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010;55: 2556-66.
61. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score. Circulation 2009;119: 1873-82.
62. Holden RM, Harman GJ, Wang M, et al. Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 2008;3: 105-10.
63. Sciahbasi A, Arcieri R, Quarto M, et al. Impact of chronic aspirin and statin therapy on presentation of patients with acute myocardial infarction and impaired renal function. Prev Cardiol 2010; 13: 18-22.
64. Ethier J, Bragg-Gresham JL, Piera L, et al. Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2007;50: 602-11.
65. Wetmore JB, Shireman TI. The ABCs of cardioprotection in dialysis patients: a systematic review. Am J Kidney Dis 2009;53: 457-66.
66. Keltai M, Tonelli M, Mann JF, et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil 2007;14: 312-8.
67. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010;122: 1056-67.
68. Palmer SC, Di Micco L, Razavian M, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;156: 445-59.
69. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and metaregression of randomised controlled trials. BMJ 2008; 336: 645-51.
70. Upadhyay A, Earley A, Lamont JL, et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;157: 251-62.
71. Slinin Y, Ishani A, Rector T, et al. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. Am J Kidney Dis 2012;60: 747-69.
72. Mason NA, Bailie GR, Satayathum S, et al. HMG-CoA reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 2005;45: 119-26.
73. Wanner C, Krane V, MärzW, et al. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353: 238-48.
74. März W, Genser B, Drechsler C, et al. German Diabetes and Dialysis Study Investigators. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 2011;6: 1316-25.
75. Fellström BC, Jardine AG, Schmieder RE, et al. AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl JMed 2009;360: 1395-407.
76. Holdaas H, Holme I, Schmieder RE, et al. AURORA Study Group. Rosuvastatin in diabetic hemodialysis patients. J AmSoc Nephrol 2011;22: 1335-41.
77. Baigent C, Landray MJ, Reith C, et al. SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-92.
78. Le Feuvre C. Angioplasty and stenting in patients with renal disease. Heart 2000;83: 7-8.
79. Szczech LA, Reddan DN, OwenWF, et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int 2001;60: 292-9.
80. Koyanagi T, Nishida H, Kitamura M, et al. Comparison of clinical outcomes of coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in renal dialysis patients. Ann Thorac Surg 1996;61: 1793-6.
81. Wong JA, Goodman SG, Yan RT, et al. Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. Eur Heart J 2009; 30: 549-57.
82. Ziada KM. Coronary revascularization in end-stage renal disease. Curr Cardiol Rep 2007;9: 389-95.